Tamara van Donge

Simplification of methadone dosing in preterm neonates 91 5 21. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug TransportInsights from Methadone Interactions with Ritonavir/Indinavir. The Journal of the American Society of Anesthesiologists. 2009;110(3):660-672. 22. Dale O, Sheffels P, Kharasch ED. Bioavailabilities of rectal and oral methadone in healthy subjects. British journal of clinical pharmacology. 2004;58(2):156-162. 23. Owen JS, Fiedler-Kelly J. Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models. John Wiley & Sons; 2014. 24. Team RC. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Austria. In: URL http://www. R-project. org; 2018. 25. Mould D, Upton R. Basic concepts in population modeling, simulation, and model‐based drug development. CPT: pharmacometrics & systems pharmacology. 2012;1(9):1-14. 26. Mould D, Upton RN. Basic concepts in population modeling, simulation, and model‐based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT: pharmacometrics & systems pharmacology. 2013;2(4):1-14. 27. Koch G, Schropp J. Mathematical concepts in pharmacokinetics and pharmacodynamics with application to tumor Growth. In: Nonautonomous dynamical systems in the life sciences. Springer; 2013:225-250. 28. Bonate PL, Steimer J-L. Pharmacokinetic-pharmacodynamic modeling and simulation. Springer; 2011. 29. Ward RM, Drover DR, Hammer GB, et al. The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. Pediatric Anesthesia. 2014;24(6):591-601. 30. Kristensen K, Blemmer T, Angelo HR, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Therapeutic drug monitoring. 1996;18(3):221-227. 31. Yang F, Tong X, McCarver DG, Hines RN, Beard DA. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. Journal of pharmacokinetics and pharmacodynamics. 2006;33(4):485-518. 32. Salem AH, Fletcher CV, Brundage RC. Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrobial agents and chemotherapy. 2014;58(1):136-143. 33. Pearce RE, Gaedigk R, Twist GP, et al. Developmental expression of CYP2B6: a comprehensive analysis of mRNA expression, protein content and bupropion hydroxylase activity and the impact of genetic variation. Drug Metabolism and Disposition. 2016;44(7):948-958. 34. Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life sciences. 1997;61(26):2567-2574. 35. Cole F, Wegner DJ, Davis JM. The genomics of neonatal abstinence syndrome. Frontiers in Pediatrics. 2017;5:176. 36. Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone PharmacogeneticsCYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology: The Journal of the American Society of Anesthesiologists. 2015;123(5):1142-1153. 37. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV‐infected individuals. Clinical pharmacology & therapeutics. 2007;81(4):557-566. 38. Jansson LM, Choo R, Velez ML, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. 2008;121(1):106-114.